Intravacc and Primrose Bio Renew Strategic Partnership to Advance Conjugate Vaccine Development
Key Insights
Intravacc (search) and Primrose Bio (search) have renewed their strategic partnership to enhance conjugate vaccine development and manufacturing capabilities for third-party clients.
The collaboration combines Intravacc (search)'s expertise in vaccine conjugation and GMP production with Primrose Bio (search)'s PeliCRM197® (search) carrier protein technology.
The partnership creates a seamless full-service solution spanning from early-stage development through clinical manufacturing for vaccine developers.
Intravacc (search), a leading global contract development and manufacturing organization (CDMO) specializing in infectious disease (search) and therapeutic vaccines, and Primrose Bio (search), a biotechnology company focused on next-generation therapeutic manufacturing technologies, have renewed their strategic partnership to enhance conjugate vaccine development and supply capabilities. The collaboration aims to provide third-party vaccine developers with comprehensive solutions spanning conjugation, manufacturing, and supply chain management.
Partnership Strengthens Vaccine Development Capabilities
The renewed partnership leverages the complementary strengths of both organizations to address critical gaps in the conjugate vaccine development landscape. Intravacc (search) contributes comprehensive technical expertise, state-of-the-art facilities, and robust capabilities in antigen conjugation process development, scale-up, and GMP production of conjugate vaccines. Primrose Bio (search) complements these capabilities with ultra-pure production, supply chain management, and regulatory support for its PeliCRM197® (search) carrier protein.
"We are excited to renew our partnership with Primrose Bio (search). By combining our expertise with Primrose's cutting-edge technologies, we aim to revolutionize the landscape of conjugate vaccine development, ultimately benefiting millions worldwide," said Ivo Lemmens, Intravacc (search)'s managing director.
Industry-Leading Carrier Protein Technology
Central to the partnership is Primrose Bio (search)'s PeliCRM197® (search) carrier protein, which serves as a vital ingredient in conjugate vaccine formulations. The protein represents the only CRM197 used in commercial vaccines that is available for purchase, offering flexibility for vaccine developers across different stages of development. PeliCRM197® is available in quantities ranging from milligrams to kilograms and in various grades suitable for both research applications and GMP manufacturing requirements.
Andrew Burch, Primrose Bio (search)'s CEO, emphasized the strategic value of the collaboration: "Expanding the capability of our PeliCRM197® (search) franchise with Intravacc (search) now creates a full-service solution for our early-stage customers and partners needing vaccine conjugation development. With both companies having direct product experience in preclinical, manufacturing, and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry as a whole."
Comprehensive Development Platform
The partnership creates an integrated platform that supports the complete vaccine development pathway from early-stage research through Phase I/II clinical production. Intravacc (search)'s expertise spans cell-culture, bacterial, and conjugation platforms, while maintaining extensive GMP capabilities that enable technology transfer and scalable vaccine solutions. This comprehensive approach allows partners to accelerate development timelines, reduce risk, and efficiently advance innovative vaccines toward clinical testing.
Industry Impact and Client Base
Both companies bring established relationships with major pharmaceutical partners to the collaboration. Primrose Bio (search)'s technologies are currently utilized by top pharmaceutical companies including Merck (search), Jazz Pharmaceuticals, Serum Institute of India, and Alvogen in their approved products. Additional clients include Arcellx, Arcturus (search), and other prominent industry players, demonstrating the commercial viability and regulatory acceptance of the combined platform.
The strategic alignment between Intravacc (search) and Primrose Bio (search) represents a significant development in conjugate vaccine manufacturing capabilities, potentially accelerating the development of next-generation vaccines for infectious diseases and therapeutic applications. The partnership addresses industry needs for streamlined development processes and reliable supply chain management in the increasingly complex vaccine development landscape.